Hydroxyurea's Effects on Bone Loss in Sickle Cell Mice
Author Information
Author(s): Tripathi Ashish Kumar, Dabeer Sadaf, Song Jun, Vikulina Tatyana, Roser-Page Susanne, Alvarez Jessica A., Archer David R., Weitzmann M. Neale
Primary Institution: Emory University
Hypothesis
Does hydroxyurea ameliorate bone disease in sickle cell disease models?
Conclusion
Hydroxyurea improves cortical bone loss but exacerbates trabecular bone loss in sickle cell mice.
Supporting Evidence
- Hydroxyurea treatment led to significant declines in trabecular bone mass.
- Bone turnover was driven to a low state by hydroxyurea.
- Hydroxyurea improved cortical bone loss in mature sickle cell mice.
Takeaway
Hydroxyurea helps some bones but makes others worse in mice with sickle cell disease.
Methodology
The study used high-resolution micro-computed tomography to analyze bone structure in sickle cell mice treated with hydroxyurea.
Potential Biases
Potential bias in animal model selection and treatment administration.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Sickle cell disease mice (Townes model) and wild-type mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website